Ireland
# |
Name |
Gross Profit |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 2.40 B
|
Dec. 31, 2023 | USD 200.24 | -8.14% |
|
Ireland |
|
2 |
USD 0.00
|
Dec. 31, 2023 | USD 0.02 | -6.17% |
|
Ireland |
|
3 |
USD -315.00 K
|
Dec. 31, 2023 | USD 8.19 | -1.92% |
|
Ireland |
|
4 |
USD -1.75 M
|
Dec. 31, 2023 | USD 1.60 | -2.44% |
|
Ireland |
|
5 |
USD -2.57 M
|
Dec. 31, 2023 | USD 3.72 | -0.53% |
|
Ireland |
|
6 |
USD -129.20 M
|
Dec. 31, 2023 | USD 12.67 | -3.50% |
|
Ireland |
The Clinical Trials company in Ireland with the highest Gross Profit is ICON Public Limited Company (NasdaqGS: ICLR) at USD 2.40 B.
The Clinical Trials company in Ireland with the lowest Gross Profit is Prothena Corporation plc (NasdaqGS: PRTA) at USD -129.20 M.
The top 10 Clinical Trials companies in Ireland by Gross Profit are ICON Public Limited Company, Ovoca Bio plc, GH Research PLC, Iterum Therapeutics plc, Mural Oncology plc and Prothena Corporation plc.
The bottom 10 Clinical Trials companies in Ireland by Gross Profit are Prothena Corporation plc, Mural Oncology plc, Iterum Therapeutics plc, GH Research PLC, Ovoca Bio plc and ICON Public Limited Company.